Evidence map›Paper›PMID 41267780›Full record

ReviewFrontiers in cellular and infection microbiology2025

The gut microbiome as a major source of drug-resistant infections: emerging strategies to decolonize and target the gut reservoir.

Ishrya Sharma, Drishya Sudarsanan, Shannon Moonah

Abstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026
    Review
  2. A single amino acid substitution determines susceptibility ofFrontiers in cellular and infection microbiology · 2026
    Article
  3. Review
  4. Article
  5. First Report of a Carbapenem-ResistantInfection and drug resistance · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ishrya SharmaDepartment of Medicine, University of Florida, Gainesville, FL, United States.
Drishya SudarsananDepartment of Medicine, University of Florida, Gainesville, FL, United States.
Shannon MoonahDepartment of Medicine, University of Florida, Gainesville, FL, United States.

Funding

CD74 and Wound HealingR01DK131313 · NIDDK · UNIVERSITY OF VIRGINIA · PI Shannon Moonah · 2022 to 2026
$1.8M
NIDDK NIH HHS R01 DK131313
6 · The paper itself

Abstract

Infections caused by antimicrobial-resistant bacteria represent a significant global health crisis that continues to worsen, creating an urgent need for alternative treatment and prevention strategies. A major source of drug-resistant bacteria is the human gut. The gut microbiota consists of bacteria that are frequently exposed to antibiotics, leading to selective pressure that promotes the development of resistant strains such as carbapenem-resistant Enterobacterales (CRE) and vancomycin-resistant enterococci (VRE). These drug-resistant bacteria can spread from the gut to other body sites, leading to hard-to-treat and potentially life-threatening infections such as bacteremia, surgical site infections, and urinary tract infections. Targeting the gut reservoir is essential in the fight against antimicrobial resistance. In this review, we focus on emerging non-antibiotic strategies aimed at eliminating drug resistant bacteria from the gut before they cause invasive infections, with particular emphasis on clinical evidence. Approaches discussed include fecal microbiota transplantation, bacteriophage therapy, antimicrobial peptides, probiotics, and dietary interventions. Optimizing these strategies, while continuing to explore newer approaches, will be essential to combat the growing threat of drug-resistant infections.

Indexed as

BacteriaBacterial InfectionsDrug Resistance, BacterialGastrointestinal MicrobiomeAnti-Bacterial AgentsAntimicrobial PeptidesFecal Microbiota TransplantationHumansPhage TherapyProbioticsAnti-Bacterial AgentsAntimicrobial Peptidesantibiotic resistanceantimicrobial pepidesbacteriabacteriophagedietary interventionsfecal micriobiota transplantationgut microbiomeprobiotics

Identifiers

PMID41267780
PMCPMC12626988

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.